在T1的膀胱癌有做第二次膀胱腫瘤切除術的結果 - 奇美醫院的經驗
曾文歆、廖建華、沈坤宏、黃冠華1、陳俊豪、洪順興2、劉建良、蘇家震、王致丞
奇美醫學中心 外科部 泌尿外科；1泌尿腫瘤科；2佳里奇美醫院 外科部 泌尿外科
Outcome of second-look transurethral resection bladder tumor for superficial t1 bladder cancer - chi mei medical center experience
Wen-Hsin Tseng、Alex Chien-Hwa Liao、Kun-Hung Shen、Steven K. Huang1、 Chun-Hao Chen、Shun-Hsing Hung2、Chien-Liang Liu、Chia-Cheng Su、Jhih-Cheng Wang
Division of Urology, Department of Surgery；1Division of Uro-Oncology Chi Mei Medical Center, Tainan, Taiwan；
2Division of Urology, Department of Surgery, Chi Mei Medical Center, Chiali, Tainan, Taiwan
Purpose:
The aim of this article was to evaluate the outcome of second-look transurethral resection of bladder tumor (TUR-BT) for superficial T1 bladder cancer.
Materials and Methods:
During March 2013 to December 2015, total 270 patients accepted TUR-BT and pathology revealed urothelial carcinoma were enrolled. There were 109 patients newly diagnosed T1 urothelial carcinoma in bladder. Six-five of 109 patients (60%) were received second TUR-BT within 2~8 weeks after the initial resection. We assessed the pathological staging of the second-look TURBT.
Results:
There were 12 of 65 patients (18%) who underwent second-look TUR-BT had residual tumors from pathological report, 1 had pTa, 6 had carcinoma in situ (CIS), 4 had pT1, and 1 had pT2 disease.
Conclusion:
According to our data, the residual tumors rate of second-look TURBT were 18%. And through second-look TURBT, we could early diagnoses the recurrence or upstaging and decided the next step if the residual tumor was found.